Literature DB >> 29793829

Best practices for the use of intracerebroventricular drug delivery devices.

Irene Slavc1, Jessica L Cohen-Pfeffer2, Sridharan Gururangan3, Jeanne Krauser3, Daniel A Lim4, Marcos Maldaun5, Christoph Schwering6, Adam J Shaywitz2, Manfred Westphal6.   

Abstract

For decades, intracerebroventricular (ICV), or intraventricular, devices have been used in the treatment of a broad range of pediatric and adult central nervous system (CNS) disorders. Due to the limited permeability of the blood brain barrier, diseases with CNS involvement may require direct administration of drugs into the brain to achieve full therapeutic effect. A recent comprehensive literature review on the clinical use and complications of ICV drug delivery revealed that device-associated complication rates are variable, and may be as high as 33% for non-infectious complications and 27% for infectious complications. The variability in reported safety outcomes may be driven by a lack of consensus on best practices of device use. Numerous studies have demonstrated that employing strict aseptic techniques and following stringent protocols can dramatically reduce complications. Key practices to be considered in facilitating the safe, long-term use of these devices are presented.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Consensus; Drug delivery; ICV; Intracerebroventricular; Intrathecal; Ommaya reservoir; Rickham reservoir

Mesh:

Substances:

Year:  2018        PMID: 29793829     DOI: 10.1016/j.ymgme.2018.05.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.

Authors:  Grant L Austin; Zoe R Simmons; Jack E Klier; Alberto Rondon; Brad L Hodges; Robert Shaffer; Nadine M Aziz; Tracy R McKnight; James R Pauly; Dustin D Armstrong; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Pharm       Date:  2019-08-02       Impact factor: 4.939

Review 2.  Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.

Authors:  Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry
Journal:  Trends Mol Med       Date:  2019-09-12       Impact factor: 11.951

3.  Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain.

Authors:  Smrithi Padmakumar; Gregory Jones; Grishma Pawar; Olga Khorkova; Jane Hsiao; Jonghan Kim; Mansoor M Amiji; Benjamin S Bleier
Journal:  J Control Release       Date:  2021-01-21       Impact factor: 9.776

4.  Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice.

Authors:  Feng Wang; Derek R Moen; Chelsee Sauni; Shih-Hsin Kan; Shan Li; Steven Q Le; Brett Lomenick; Xiaoyi Zhang; Sean Ekins; Srikanth Singamsetty; Jill Wood; Patricia I Dickson; Tsui-Fen Chou
Journal:  Mol Pharm       Date:  2020-12-15       Impact factor: 4.939

5.  Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.

Authors:  Dolan Sondhi; Stephen M Kaminsky; Neil R Hackett; Odelya E Pagovich; Jonathan B Rosenberg; Bishnu P De; Alvin Chen; Benjamin Van de Graaf; Jason G Mezey; Grace W Mammen; Denesy Mancenido; Fang Xu; Barry Kosofsky; Kaleb Yohay; Stefan Worgall; Robert J Kaner; Mark Souwedaine; Bruce M Greenwald; Michael Kaplitt; Jonathan P Dyke; Douglas J Ballon; Linda A Heier; Szilard Kiss; Ronald G Crystal
Journal:  Sci Transl Med       Date:  2020-12-02       Impact factor: 17.956

6.  Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.

Authors:  J Schaefers; L J van der Giessen; C Klees; E H Jacobs; S Sieverdink; M H G Dremmen; J K H Spoor; A T van der Ploeg; J M P van den Hout; H H Huidekoper
Journal:  Orphanet J Rare Dis       Date:  2021-05-14       Impact factor: 4.123

7.  Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.

Authors:  Christoph Schwering; Gertrud Kammler; Eva Wibbeler; Martin Christner; Johannes K-M Knobloch; Miriam Nickel; Jonas Denecke; Michael Baehr; Angela Schulz
Journal:  J Child Neurol       Date:  2021-02-05       Impact factor: 1.987

Review 8.  Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid.

Authors:  Yuji Sato; Kohtaro Minami; Toru Hirato; Kazunori Tanizawa; Hiroyuki Sonoda; Mathias Schmidt
Journal:  Metab Brain Dis       Date:  2022-01-28       Impact factor: 3.655

9.  Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach.

Authors:  Smrithi Padmakumar; Gregory Jones; Olga Khorkova; Jane Hsiao; Jonghan Kim; Benjamin S Bleier; Mansoor M Amiji
Journal:  Biomaterials       Date:  2021-06-30       Impact factor: 12.479

10.  Intracerebroventricular Administration of hNSCs Improves Neurological Recovery after Cardiac Arrest in Rats.

Authors:  Zhuoran Wang; Jian Du; Brittany Bolduc Lachance; Conrad Mascarenhas; Junyun He; Xiaofeng Jia
Journal:  Stem Cell Rev Rep       Date:  2020-11-02       Impact factor: 6.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.